Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Dr. Naveen Pemmaraju
Dr. Naveen Pemmaraju

In a study of 1054 patients with primary MF,

Approximately 90% of patients for whom data were available had palpable splenomegaly at diagnosis1

Data were available for 768 patients, 681 of whom had palpable splenomegaly.1

Due to this high rate of splenomegaly at diagnosis, Naveen Pemmaraju, MD, performs spleen assessment at baseline and consistently throughout management as part of his patient care.

MF is a serious disease that may require active management at diagnosis2

Image of text  that says In a study of patients with primary myelofibrosis (MF), approximately 90% (375/428) of evaluable patients were considered to be intermediate- or high-risk within 1 year of diagnosis
Image of text  that says In a study of patients with primary myelofibrosis (MF), approximately 90% (375/428) of evaluable patients were considered to be intermediate- or high-risk within 1 year of diagnosis

Any one of the following risk factors* indicates a patient is already intermediate-risk1,3:

  • Hemoglobin <10 g/dL
  • Circulating blast cells ≥1%
  • Leukocyte count >25 x 109/L
  • Platelet count <100 x 109/L
  • Age >65 years
  • Red cell transfusion dependency
  • Constitutional symptoms
  • Unfavorable karyotype

*As included in the Dynamic International Prognostic System Plus tool.

Image of Naveen Pemmaraju, MD
Splenomegaly is an important clinical indicator in patients with MF and in my practice, I find that spleen assessment can be a powerful tool to help monitor disease progression.
—Naveen Pemmaraju, MD

References: 1. Cervantes F, Dupriez B, Pereira A, et al. Blood. 2009;113(13):2895-2901. 2. Barbui T, Barosi G, Birgegard G, et al. J Clin Oncol. 2011;29(6):761-770. 3. Gangat N, Caramazza D, Vaidya R, et al. J Clin Oncol. 2011;39(4):392-397.

Get expert insights and other support for critical MF topics

Spleen assessment

Discover why spleen palpation is so vital in MF diagnosis and disease management and learn Naveen Pemmaraju, MD's technique for spleen measurement.

Symptoms

Learn about the prevalence and effect of symptoms associated with MF, and access a resource focused on symptoms with insights by Ruben A. Mesa, MD, FACP.

Resources

Browse our robust library of MF resources to support your practice.